Published
2022-11-21
Section
Review Article
How to Cite
Importance of Nanomedicines for cancer therapy - Review Article
Anshul Kadwe
Second Year Bachelor of Technology Department of Polymer Engineering and Technology
Payal Nikam
Department of Oils, Oleochemicals and Surfactants Technology
Tejal Thakare
Department of Oils, Oleochemicals and Surfactants Technology
DOI: https://doi.org/10.36664/bt/2022/v69i1/172494
Keywords: Nanomedicine, cancer therapy, drug delivery, nanoparticles, chemotherapeutic agents.
Abstract
Due to the restrictions of present day most cancers treatments, nanotechnology has been used to expand extra powerful and more secure most cancers treatments. The improvement of nanomedicines has made excellent development in overcoming a number of the issues related to conventional most cancers treatments, including negative drug solubility, negative concentrated on, and drug resistance. As a result of nanoparticle modulation, the pharmacokinetics of the drug may be improved, resulting in higher concentrated on and less facet effects. In addition, nanoparticles can bind to ligands that mainly target most cancers cells. Furthermore, techniques to result in drug launch in tumors via way of means of leveraging tumor traits have proven that they beautify the effectiveness of centered drug delivery. Despite a few medical success, maximum nanomedicines do now no longer attain the clinic. Clinical translation is hampered via way of means of many factors, consisting of layout complexity, incomplete expertise of organic mechanisms, and excessive production demands. Clinical translation can be progressed via means of integrating information from exceptional disciplines which includes chemistry and tumor pathophysiology. Understanding how nanoparticle change influences organic structures is crucial for growing greater powerful nanomedicines. This evaluation summarizes the important thing achievements of nanomedicines, consisting of excessive molecular weight nanoparticles to enhance drug shipping and release, and techniques to conquer drug resistance.
Downloads
References
X. Xue, A. Lindstrom, H. Qu, and Y. Li, “Recent advances on small-molecule nanomedicines for cancer treatment,” Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, vol. 12, no. 3. Wiley-Blackwell, May 01, 2020. doi: 10.1002/wnan.1607.
E. Blanco, A. Hsiao, A. P. Mann, M. G. Landry, F. Meric-Bernstam, and M. Ferrari, “Nanomedicine in cancer therapy: Innovative trends and prospects,” Cancer Science, vol. 102, no. 7. pp. 1247–1252, Jul. 2011. doi: 10.1111/j.1349-7006.2011.01941.x.
R. van der Meel, T. Lammers, and W. E. Hennink, “Cancer nanomedicines: oversold or underappreciated?,” Expert Opinion on Drug Delivery, vol. 14, no. 1. Taylor and Francis Ltd, pp. 1–5, Jan. 02, 2017. doi: 10.1080/17425247.2017.1262346.
D. Rani, V. H. Somasundaram, S. Nair, and M. Koyakutty, “Advances in Cancer Nanomedicine Article in Journal of the Indian Institute of Science ·,” 2012. [Online].
G. H. Nam, Y. Choi, G. B. Kim, S. Kim, S. A. Kim, and I. S. Kim, “Emerging Prospects of Exosomes for Cancer Treatment: From Conventional Therapy to Immunotherapy,” Advanced Materials, vol. 32, no. 51. Wiley-VCH Verlag, Dec. 01, 2020. doi: 10.1002/adma.202002440.
Y. Yan et al., “Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy,” Frontiers in Immunology, vol. 9. Frontiers Media S.A., Jul. 27, 2018. doi: 10.3389/fimmu.2018.01739.
C. Moorthi, R. Manavalan, and K. Kathiresan, “Nanotherapeutics to Overcome Conventional Cancer Chemotherapy Limitations,” 2011. [Online].
E. Blanco, A. Hsiao, A. P. Mann, M. G. Landry, F. Meric-Bernstam, and M. Ferrari, “Nanomedicine in cancer therapy: Innovative trends and prospects,” Cancer Science, vol. 102, no. 7. pp. 1247–1252, Jul. 2011. doi: 10.1111/j.1349-7006.2011.01941.x.
Y. Wang et al., “Smart transformable nanomedicines for cancer therapy,” Biomaterials, vol. 271. Elsevier Ltd, Apr. 01, 2021. doi: 10.1016/j.biomaterials.2021.120737.
N. Bertrand, J. Wu, X. Xu, N. Kamaly, and O. C. Farokhzad, “Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology,” Advanced Drug Delivery Reviews, vol. 66. Elsevier B.V., pp. 2–25, 2014. doi: 10.1016/j.addr.2013.11.009.
C. Paus, R. van der Voort, and A. Cambi, “Nanomedicine in cancer therapy: promises and hurdles of polymeric nanoparticles,” Exploration of Medicine, Apr. 2021, doi: 10.37349/emed.2021.00040.
M. E. David and M. E. Grigore, “3 Organic and Inorganic Nano-Systems Used in Cancer Treatment,” 2017. [Online].
R. Vargas-Bernal, “Introductory Chapter: Hybrid Nanomaterials,” in Hybrid Nanomaterials - Flexible Electronics Materials, IntechOpen, 2020. doi: 10.5772/intechopen.92012.
C. M. J. Hu and L. Zhang, “Nanoparticle-based combination therapy toward overcoming drug resistance in cancer,” Biochemical Pharmacology, vol. 83, no. 8. pp. 1104–1111, Apr. 15, 2012. doi: 10.1016/j.bcp.2012.01.008.
T. Ozben, “Mechanisms and strategies to overcome multiple drug resistance in cancer,” FEBS Letters, vol. 580, no. 12. pp. 2903–2909, May 22, 2006. doi: 10.1016/j.febslet.2006.02.020.
Z. Xie et al., “Emerging combination strategies with phototherapy in cancer nanomedicine,” Chemical Society Reviews, vol. 49, no. 22. Royal Society of Chemistry, pp. 8065–8087, Nov. 21, 2020. doi: 10.1039/d0cs00215a.
A. P. Dias et al., “Dendrimers in the context of nanomedicine,” International Journal of Pharmaceutics, vol. 573. Elsevier B.V., Jan. 05, 2020. doi: 10.1016/j.ijpharm.2019.118814.
D. S. Williams, I. A. B. Pijpers, R. Ridolfo, and J. C. M. van Hest, “Controlling the morphology of copolymeric vectors for next generation nanomedicine,” Journal of Controlled Release, vol. 259, pp. 29–39, Aug. 2017, doi: 10.1016/j.jconrel.2017.02.030.
L. Zhang and R. J. Daly, “Targeting the Human Kinome for Cancer Therapy: Current Perspectives,” 2012.
S. Arany, D. S. W. Benoit, S. Dewhurst, and C. E. Ovitt, “Nanoparticle-mediated gene silencing confers radioprotection to salivary glands in vivo,” Molecular Therapy, vol. 21, no. 6, pp. 1182–1194, 2013, doi: 10.1038/mt.2013.42.
P. Gaur, D. Bose, S. Samuel, and L. M. Ellis, “Targeting Tumor Angiogenesis,” Seminars in Oncology, vol. 36, no. SUPPL. 1, Apr. 2009, doi: 10.1053/j.seminoncol.2009.02.002.
S. Parveen and S. K. Sahoo, “Polymeric nanoparticles for cancer therapy,” Journal of Drug Targeting, vol. 16, no. 2. pp. 108–123, Feb. 2008. doi: 10.1080/10611860701794353.
X. Xu, W. Ho, X. Zhang, N. Bertrand, and O. Farokhzad, “Cancer nanomedicine: From targeted delivery to combination therapy,” Trends in Molecular Medicine, vol. 21, no. 4. Elsevier Ltd, pp. 223–232, Apr. 01, 2015. doi: 10.1016/j.molmed.2015.01.001.
M. Alavi and M. Hamidi, “Passive and active targeting in cancer therapy by liposomes and lipid nanoparticles,” Drug Metabolism and Personalized Therapy, vol. 34, no. 1. De Gruyter, 2019. doi: 10.1515/dmpt-2018-0032.
J. Xiang et al., “Advanced Nano-Carriers for Anti-Tumor Drug Loading,” Frontiers in Oncology, vol. 11. Frontiers Media S.A., Sep. 16, 2021. doi: 10.3389/fonc.2021.758143.
R. Zein, W. Sharrouf, and K. Selting, “Physical Properties of Nanoparticles That Result in Improved Cancer Targeting,” Journal of Oncology, vol. 2020. Hindawi Limited, 2020. doi: 10.1155/2020/5194780.
J. Zhang, H. Tang, Z. Liu, and B. Chen, “Effects of major parameters of nanoparticles on their physical and chemical properties and recent application of nanodrug delivery system in targeted chemotherapy,” International Journal of Nanomedicine, vol. 12. Dove Medical Press Ltd., pp. 8483–8493, Nov. 28, 2017. doi: 10.2147/IJN.S148359.
N. O. Mahmoodi, A. Ghavidast, and N. Amirmahani, “A comparative study on the nanoparticles for improved drug delivery systems,” Journal of Photochemistry and Photobiology B: Biology, vol. 162. Elsevier B.V., pp. 681–693, Sep. 01, 2016. doi: 10.1016/j.jphotobiol.2016.07.037.
A. C. Marques, P. J. Costa, S. Velho, and M. H. Amaral, “Functionalizing nanoparticles with cancer-targeting antibodies: A comparison of strategies,” Journal of Controlled Release, vol. 320. Elsevier B.V., pp. 180–200, Apr. 10, 2020. doi: 10.1016/j.jconrel.2020.01.035.
M. Y. Yang, L. Tan, H. X. Wu, C. J. Liu, and R. X. Zhuo, “Dual-stimuli-responsive polymer-coated mesoporous silica nanoparticles used for controlled drug delivery,” Journal of Applied Polymer Science, vol. 132, no. 32, Aug. 2015, doi: 10.1002/app.42395.
P. Hervella, V. Lozano, M. Garcia-Fuentes, and M. J. Alonso, “Nanomedicine: New challenges and opportunities in cancer therapy,” Journal of Biomedical Nanotechnology, vol. 4, no. 3, pp. 276–292, 2008, doi: 10.1166/jbn.2008.339.
